SS 33 - GI 2: Giving Radiation a Boost in Pancreatic Cancer and Responding to the Call for Esophageal Cancer

Presentations

• 08:00am - 08:10am PT

  Sequential Chemo-Immunotherapy as a Novel Bridging Strategy for Non-Complete Responders after Neoadjuvant Chemoradiotherapy in Esophageal Cancer: First Prospective Phase 2 Trial Challenging Immediate Surgery Paradigm

  Speaker: Qifeng Wang, MD - Sichuan Cancer Hospital and Institute, Chengdu
• 08:10am - 08:20am PT

  Definitive Stereotactic Body Radiation Therapy for Resectable Non-Metastatic Pancreatic Ductal Adenocarcinoma: A Multi-Center Retrospective Analysis

  Speaker: Michael Chuong, MD - Miami Cancer Institute at Baptist Health South Florida, Miami
• 08:20am - 08:30am PT

  A Safety Study of Intraoperative Radiation Therapy Following Stereotactic Body Radiation Therapy and Multi-Agent Chemotherapy in the Treatment of Localized Pancreatic Adenocarcinoma

  Speaker: Abhinav Reddy, MD - Northside Hospital, Atlanta
• 08:30am - 08:40am PT

  Maximal Ablative Irradiation because of Encasement for Patients with Potentially Resectable Locally Advanced Pancreatic Cancer: Final Results of Phase II MAIBE Trial

  Speaker: Marsha Reyngold, MD, PhD - Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York
• 08:40am - 08:50am PT

  Patient-Specific TP53-Mutant Circulating Tumor DNA as a Prognostic Biomarker for Detection of Minimal Residual Disease after Neoadjuvant Concurrent Chemoradiotherapy followed by Esophagectomy in Locally Advanced Esophageal Squamous Cell Carcinoma

  Speaker: Jason Chia-Hsien Cheng, MD, PhD, MS, FASTRO - National Taiwan University Hospital, Taipei
• 08:50am - 09:00am PT

  Discussant

  Speaker: Ethan Ludmir, MD - The University of Texas MD Anderson Cancer Center, Houston